Explore the Agenda
Personalis is a provider of advanced genomic sequencing and analytics solutions that support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Their patented ACE (Accuracy & Content Enhanced) Technology forms the foundation of all Personalis products. ACE Technology improves every individual step in the next-generation sequencing (NGS) process, from nucleic acid extraction to sequencing assays, to data analytics. This makes it possible for them to achieve augmented coverage of difficult-to-sequence genomic regions that are missed with the use of conventional sequencing techniques.
Using this comprehensive approach, they can provide you with genomic data of the highest quality and accuracy to drive immuno-oncology clinical and biomarker discovery programs, thus enabling the rational design and development of effective cancer immunotherapies.
Register your interest today to join Personalis for an in-depth, interactive engager session and explore how ultra-sensitive MRD detection and advanced genomic sequencing are reshaping oncology clinical trials. Discover how these technologies can be integrated into your programs to strengthen patient selection, generate earlier signals, and accelerate therapeutic development.
Personalis Engager
3:00 pm Integrating ctDNA Monitoring in Clinical Trial Development — Real-World Experience
What We Will Discuss:
- Overview of Personalis and high-level recent clinical evidence
- Integration of MRD in clinical trial development
- Regulatory and quality hurdles for ultra-high sensitivity assays
This collaborative session brings together industry leaders to discuss the integration of ctDNA monitoring into clinical trial development. Panellists will share their organizational strategies, implementation experiences, key opportunities, and internal adoption efforts. The Engager will also cover key opportunities to accelerate adoption, strategies for securing leadership alignment, and how Personalis can support these initiatives. Attendees will gain real-world insights into regulatory frameworks, academic requirements, and biotech perspectives, while also exploring how Personalis can further support pharma’s ctDNA integration goals.